Immix: Positive Results in DARZALEX-Relapsed/Refractory AL Amyloidosis Phase 1b/2a Trial

 

• 8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201
• 100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10^-5) was demonstrated by NXC-201 with zero ICANs, zero grade 4 CRS
• 62% (5/8) had NYHA classification III or IV heart failure prior to treatment with NXC-201
• Best responder duration of response was 16.5 months with response ongoing as of the data cutoff date of May 11, 2023

https://www.biospace.com/article/releases/immix-biopharma-announces-positive-nxc-201-clinical-results-at-asgct-100-percent-overall-response-rate-in-darzalex-relapsed-refractory-al-amyloidosis-with-zero-icans-in-ongoing-nexicart-1-phase-1b-2a-clinical-trial/